Insulin Lispro-Aabc shortage status
1 active shortage notice across 1 country.
Last updated 2 Aug 2026 · sourced from official medicines regulators
- Generic name (INN)
- Insulin Lispro-Aabc
- Brand names
- Lyumjev Tempo Pen
- Class
- Auto-created by U.S. Food and Drug Administration — Drug Shortages scraper
Where Insulin Lispro-Aabc is in shortage
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| United States | critical | 1 | 24 Oct 2025 | — | FDA |
Why Insulin Lispro-Aabc is in shortage
- product discontinuation — e.g. “A business decision was made to discontinue manufacture of the drug.” (United States)
Frequently asked questions
Is Insulin Lispro-Aabc currently in shortage?
Yes. As of the latest regulator updates, Insulin Lispro-Aabc has 1 active shortage notice across 1 country (United States). Status is refreshed daily from official regulatory sources.
Why is Insulin Lispro-Aabc in shortage?
Regulators attribute the current Insulin Lispro-Aabc shortages to product discontinuation. The exact cause varies by country and product — each notice on this page links to the official source.
Where does this Insulin Lispro-Aabc shortage data come from?
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Get alerted when Insulin Lispro-Aabc status changes
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.